Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioMarin Pharmaceutical (BMRN) Stock Price & Analysis

2,472 Followers

BMRN Stock Chart & Stats

$56.03-$0.09(-0.16%)
At close: 4:00 PM EST
$55$60$65$70Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$55.00 - $56.08
52-Week Range
$49.26 - $70.98
Previous Close
$56.12
Volume
N/A
Average Volume (3M)
2.56M
Market Cap
$10.85B
Enterprise Value
$15.09B
Total Cash (Recent Filing)
$736.01M
Total Debt (Recent Filing)
$4.19B
Price to Earnings (P/E)
―
Beta
0.50
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.82
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Broad Revenue And Patient Growth

Strong growth across revenue and treated-patient counts indicates broad adoption rather than reliance on a single product. Expanding use of multiple rare-disease therapies can deepen commercial scale, support durable cash generation, and reinforce BioMarin’s position with specialists and payers.

Strong Cash Generation

Healthy operating and free cash flow provide internal funding for research, commercialization, and business development without relying entirely on external financing. This cash-generation base improves resilience while BioMarin expands its marketed portfolio and advances additional rare-disease programs.

Royalty Monetization And IP Resolution

The global license converts BioMarin’s patent position into a defined multi-year royalty stream while resolving related litigation and preserving non-interference commitments. That adds recurring revenue potential and clarifies the competitive and intellectual-property landscape around CNP therapies.

Bears Say

Sharp Profitability Compression

The move from solid prior profitability to slightly negative net margin and sharply lower EBIT margin weakens earnings quality and reduces the company’s ability to convert revenue growth into dependable profits. Recovery depends on controlling operating costs and absorbing recent business investments.

Meaningfully Higher Leverage

The substantial increase in debt relative to equity reduces financial flexibility compared with BioMarin’s recent position. Higher leverage can constrain capital allocation, increase sensitivity to weaker earnings, and make it more important that cash generation remains sufficient to fund investment and obligations.

Acquisition-related Earnings Burden

Recent acquisitions and licensing activity are expanding the pipeline but currently impose significant acquired research costs, operating expenses, and higher commercial overhead. This creates a near-term earnings drag and raises execution requirements for synergies and future assets to justify the investment.

BioMarin Pharmaceutical News

BMRN FAQ

What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $49.26 and its highest was $70.98 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.85B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 108 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Nov 02, 2026. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.279.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.82.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 193,694,730 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.23 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went down -3.099%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Hedge funds hold BioMarin Pharmaceutical shares: the largest hedge-fund position in BioMarin Pharmaceutical is 71,884,216 shares, and hedge funds increased their holdings by 2.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology